HOOKVAC

Developing and testing a novel, low-cost, effective HOOKworm VACcine to control human hookworm infection in endemic countries

Objective

HOOKVAC will address 4 main objectives:
1. Establish safety and immunogenicity of the vaccine candidate in an endemic population;
2. Improve the manufacturing process;
3. Provide clinical proof of concept;
4. Improve accessibility of the vaccine in endemic areas.

Background

Approx. 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas.

ookworm Vaccine Will Be Tried in Africa’

Articles

New York Times Parasites: Hookworm Vaccine Will Be Tried in Africa

University of Amsterdam Tackling hookworm head-on [pdf]

The Sabin Vaccine Institute Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

Summary

Name: HOOKVAC: Developing and testing a novel, low-cost, effective HOOKworm VACcine to control human hookworm infection in endemic countries
Status: Active
Principal Investigator: Remko van Leeuwen
Departments(s): AMC Department of Infectious Diseases
Partners: AMC

Albert B. Sabin Vaccine Institute (USA)

Eberhard Karls Universitaet Tuebingen (Germany)

Centre de Recherches Medicales de Lamberéné (Gabon)

Q-Biologicals (Belgium)

Pharmidex Pharmaceutical Services (United Kingdom)

Academisch Ziekenhuis Leiden – Leids Universitair Medisch Centrum (Netherlands)

Baylor College of Medicine (USA)

George Washington University (USA)

Contact information: Project Coordinator: Remko van Leeuwen (r.vanleeuwen@aighd.org)
Duration: Start date: 1 October 2013

Duration: 48 months

End date: 1 October 2017

Funded by: European Union’s Seventh Framework Programme

7

Countries: Netherlands
Germany
Belgium
Gabon
United Kingdom
United States
Publications: